Neisseria meningitidis serogroup Y (N. meningitidis serogroup Y)

Neisseria meningitidis serogroup Y is a strain of the encapsulated, Gram-negative diplococcal bacterium Neisseria meningitidis. Serogroup Y is defined by the presence of a specific capsular polysaccharide composed of sialic acid, which enables immune evasion and contributes to pathogenicity. This serogroup is one of five most clinically relevant groups (A, B, C, W, and Y) causing invasive meningococcal disease worldwide. The bacterium colonizes the human nasopharynx, may persist asymptomatically, or invade the bloodstream and central nervous system, causing meningitis or septicemia. Key virulence factors include the capsule, lipooligosaccharide endotoxin, factor H binding protein, and mechanisms for antigenic variation. Serogroup Y is a principal target for quadrivalent meningococcal conjugate vaccines (MenACWY), and for clinical therapy, antibiotics such as ceftriaxone are used. Diagnosis and monitoring often rely on serogroup-typing and detection of key outer membrane proteins or capsule antigens. Public health challenges include rapid disease progression, the necessity for immediate therapy, and gaps in vaccine coverage.

Other names

Meningococcus serogroup YNmYMeningococci group YN. meningitidis group Y

Antibiotics: Inhibit cell wall synthesis (e.g., beta-lactams) or protein synthesis (rifampin, ciprofloxacin) Vaccines: Induce immunity by stimulating antibody production against serogroup-specific capsular polysaccharide antigens